[Retracted] Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis

Table 1

Basic characteristics of the included studies.

References	Sample size (T/C)	Men/women	Age (years) (mean ± SD) (T/C)	T	C	Main outcomes
Xu et al. [27]	36/36	45/27	47.75 ± 11.05/48.22 ± 10.14	RTX + methylprednisolone	Methylprednisolone	Total effective rate, ALB, adverse reactions
Liu et al. [28]	62/87	109/38	54.2 ± 13.4/51.9 ± 10.5	RTX + rormone	Tacrolimus + rormone	Total effective rate, serum creatinine, ALB, adverse reactions
Zhang et al. [29]	38/38	48/28	42.31 ± 2.16/42.28 ± 2.17	RTX + methylprednisolone	Tripterygium glycosides	Total effective rate, serum creatinine
Xu [30]	17/18	23/12	48.71 ± 13.67/50.28 ± 8.14	RTX	Cyclophosphamide + rormone	Total effective rate, serum creatinine, ALB
Zhu et al. [31]	26/41	50/17	41.73 ± 14.89/44.34 ± 10.57	RTX + tacrolimus	Tacrolimus	Serum creatinine, ALB, adverse reactions
van den Brand et al. [32]	100/103	148/55	51.5 ± 15.9/55.3 ± 12.7	RTX	Cyclophosphamide + rormone	Adverse reactions
Dahan et al. [33]	37/38	52/23	53.0/58.5	RTX + NIAT	NIAT	Total effective rate, adverse reactions
Fervenza et al. [34]	65/65	100/30	51.9 ± 12.6/52.2 ± 12.4	RTX	Cyclosporine	Total effective rate, adverse reactions

T: trial group; C: control group.